Untitled Letters: The Warning Letter's Quieter Cousin
An untitled letter cites violations that do not meet the threshold for a warning letter. It is FDA's initial correspondence saying it considers something to be in violation, without the escalation a warning letter carries.
The name is literal: a warning letter carries the heading "WARNING LETTER", and an untitled letter does not.
Differences from a warning letter
A warning letter is reserved for violations of regulatory significance, meaning those that may lead to enforcement action if not corrected promptly.
An untitled letter covers violations below that bar. Compared with a warning letter, it:
- includes no warning that failure to correct may result in enforcement.
- requests a response but does not usually require one within 15 working days.
- carries lesser consequences for pending applications.
What it shares with a warning letter: FDA has put in writing that it considers you in violation, and the letter is a public document.
Common subjects
Untitled letters are heavily concentrated in promotional communications. The Office of Prescription Drug Promotion issues them for material it considers false or misleading, and for most sponsors an untitled letter is the realistic enforcement outcome of an MLR failure rather than a warning letter.
They also appear in clinical investigator and IRB oversight, and occasionally in device promotion.
Consequences
It is public. FDA publishes it, and anyone searching your company or product can find it. A customer or partner doing diligence will not discount it for lacking the warning-letter heading.
It establishes notice. FDA has told you in writing. A subsequent similar violation is no longer a first occurrence, and repeat conduct after an untitled letter is a common route to a warning letter.
It is fast to act on. The violations are usually narrower and more concrete than a warning letter's, so correcting them properly rarely needs a quality system overhaul.
Responding
Treat it as a warning letter with a shorter list. Correct what is cited, say what you did, and address the systemic question of how the material was approved in the first place. For a promotional letter that means the MLR process, not just the piece.
Where the letter concerns material still in circulation, stopping its use is usually the first action and should be stated as such.
Frequently asked questions
What is an untitled letter?
FDA correspondence citing violations that do not meet the threshold of regulatory significance required for a warning letter.
How is it different from a warning letter?
It carries no statement that enforcement may follow, has no formal 15 working day response requirement, and reflects a lower level of concern.
Are untitled letters public?
Yes. They are published and are findable by anyone searching the company or product.
Do I have to respond?
FDA requests a response. Not responding removes your opportunity to close the matter and leaves the violation on the record.
Who issues most untitled letters?
The Office of Prescription Drug Promotion, for promotional communications, is the largest single source.
Can an untitled letter lead to a warning letter?
Yes. It establishes notice, and a repeat of the same conduct afterwards is a common route to escalation.